Citations

Clear

3942 citation(s) found for "To, Van".

Enhancement of central nervous system remyelination in immune and non-immune experimental models of demyelination
Engelen, Baziel G.M. van , Pavelko, Kevin D. , Rodriguez, Moses

Mayo Clinic

Multiple Sclerosis Journal | November 6, 2009 | Volume: 3 | Issue: 2 | Pages: 76-79

10.1177/135245859700300203 | PMID 9291157 Get It

Studies in both humans and experimental animals indicate that there is potential for full remyelination following CNS demyelination, but the factors that control the degree of myelin repair are unknown. In the Theiler's virus model of demyelination CNS remyelination can be promoted either by global immunosuppression or by selective immunoglobulin therapy. In this paper we discuss whether immunoglobulin-mediated remyelination is a characteristic of immune-mediated demyelination, or whether immunoglobulin-mediated remyelination also occurs in the toxic-traumatic model of lysolecithin-induced demyelination. Our data support the hypothesis that even in a non-primary immune model of demyelination, manipulating the immune system can be beneficial in myelin repair.
Tumor Necrosis Factor–Like Weak Inducer of Apoptosis Stimulation of Glioma Cell Survival Is Dependent on Akt2 Function
Ensign, Shannon P. Fortin , Ennis, Matthew, Savitch, Benjamin A., Carpentieri, David , McDonough, Wendy S., Winkles, Jeffrey A. , Loftus, Joseph C. , Kingsley, Christopher , Tran, Nhan L. , Ensign, Shannon P. Fortin , Hostetter, Galen H. , Carpentieri, David , Tran, Nhan L

Mayo Clinic

Molecular Cancer Research | October 28, 2009 | Volume: 7 | Issue: 11 | Pages: 1871-1881

10.1158/1541-7786.mcr-09-0194 | PMID 19861406 Get It

Abstract Malignant gliomas are the most common primary brain tumors. Despite intensive clinical investigation and significant technical advances in surgical and radiation treatment, the impact on clinical outcome for patients with malignant gliomas is disappointing. We have previously shown that tumor necrosis factor–like weak inducer of apoptosis (TWEAK), a member of the tumor necrosis factor superfamily, can stimulate glioma cell survival via binding to the Fn14 receptor, activation of the NF-κB pathway, and upregulation of BCL-XL gene expression. Here, we show that TWEAK treatment of glioma cells leads to phosphorylation of Akt and BAD. TWEAK stimulation results in the phosphorylation of both Akt1 and Akt2. However, small interfering RNA (siRNA)–mediated depletion of either Akt1 or Akt2 showed that BAD serine 136 phosphorylation is dependent specifically on Akt2 function. Depletion of Akt2 expression by siRNA also abrogates TWEAK-stimulated glioma cell survival, whereas no effect on glioma cell survival was observed after siRNA-mediated depletion of Akt1 expression. Surprisingly, although siRNA-mediated depletion of BAD in glioma cells abrogates cytotoxic- and chemotherapy-induced apoptosis, TWEAK still displays a strong protective effect, suggesting that BAD serine 136 phosphorylation plays a minor role in TWEAK-Akt2–induced glioma cell survival. We also report here that AKT2 gene expression levels increased with glioma grade and inversely correlate with patient survival. Additionally, immunohistochemical analysis showed that Akt2 expression positively correlates with Fn14 expression in glioblastoma multiforme specimens. We hypothesize that the TWEAK-Fn14 signaling axis functions, in part, to enhance glioblastoma cell survival by activation of the Akt2 serine/threonine protein kinase. (Mol Cancer Res 2009;7(11):1871–81)
DIRECTED AGGRESSIVE BEHAVIOR IN FRONTAL LOBE EPILEPSY: A VIDEO-EEG AND ICTAL SPECT CASE STUDY
Shih, Jerry J. , Leslie‐Mazwi, Thabele M , Falcao, Germano, Gerpen, Jay Van, Gerpen, Jay A. van

Mayo Clinic

Neurology | October 22, 2009 | Volume: 73 | Issue: 21 | Pages: 1804-1806

10.1212/wnl.0b013e3181c2933f | PMID 19846832 Get It

Induction of Prostatic Intraepithelial Neoplasia and Modulation of Androgen Receptor by ETS Variant 1/ETS-Related Protein 81
Shin, Sook , Deursen, Jan M. van , Dehm, Scott M. , Tindall, Donald J., Grande, Joseph P. , Munz, Jan-Marie, Vasmatzis, George , Kim, Tae‐Dong , Jin, Fang , Janknecht, Ralf , Dehm, Scott M

Mayo Clinic

Cancer Research | September 29, 2009 | Volume: 69 | Issue: 20 | Pages: 8102-8110

10.1158/0008-5472.can-09-0941 | PMID 19789348 Get It

Abstract ETS variant 1 (ETV1), also known as ETS-related protein 81, is overexpressed in prostate tumors, but whether and how this transcription factor affects tumorigenesis has remained elusive. Here, we show that ETV1 is primarily overexpressed in the most aggressive human prostate tumors. Transgenic ETV1 mice developed prostatic intraepithelial neoplasia as well as hyperplasia/neoplasia in seminal vesicles. Moreover, ETV1 cooperated with the androgen receptor (AR) to bind to the prostate-specific antigen enhancer and stimulate gene transcription. Consistent with its ability to physically interact with AR, ETV1 rendered an ETV1 binding site–driven reporter androgen inducible, and, on the other hand, ETV1 superinduced transcription from an AR binding site on androgen stimulation. In conclusion, our study substantiates that ETV1 overexpression is an underlying cause in the development of prostate and possibly also seminal vesicle cancer. Its interaction with and activation of AR provides a molecular mechanism on how ETV1 exerts its deleterious function. Thus, inhibiting ETV1 or blocking its interaction with AR may represent novel strategies in prostate cancer therapy. [Cancer Res 2009;69(20):8102–10]
α1-Syntrophin Mutations Identified in Sudden Infant Death Syndrome Cause an Increase in Late Cardiac Sodium Current
Cheng, Jianding , Norstrand, David W. Van, Medeiros‐Domingo, Argelia , Valdivia, Carmen R. , Tan, Bi‐Hua , Ye, Bin , Kroboth, Stacie , Vatta, Matteo , Tester, David J. , January, Craig T., Makielski, Jonathan C., Ackerman, Michael J. , Medeiros-Domingo, Argelia

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | September 13, 2009 | Volume: 2 | Issue: 6 | Pages: 667-676

10.1161/circep.109.891440 | PMID 20009079 Get It

Background— Sudden infant death syndrome (SIDS) is a leading cause of death during the first 6 months after birth. About 5% to 10% of SIDS may stem from cardiac channelopathies such as long-QT syndrome. We recently implicated mutations in α1-syntrophin (SNTA1) as a novel cause of long-QT syndrome, whereby mutant SNTA1 released inhibition of associated neuronal nitric oxide synthase by the plasma membrane Ca-ATPase PMCA4b, causing increased peak and late sodium current ( I Na ) via S-nitrosylation of the cardiac sodium channel. This study determined the prevalence and functional properties of SIDS-associated SNTA1 mutations. Methods and Results— Using polymerase chain reaction, denaturing high-performance liquid chromatography, and DNA sequencing of SNTA1 ’s open reading frame, 6 rare (absent in 800 reference alleles) missense mutations (G54R, P56S, T262P, S287R, T372M, and G460S) were identified in 8 (≈3%) of 292 SIDS cases. These mutations were engineered using polymerase chain reaction–based overlap extension and were coexpressed heterologously with SCN5A, neuronal nitric oxide synthase, and PMCA4b in HEK293 cells. I Na was recorded using the whole-cell method. A significant 1.4- to 1.5-fold increase in peak I Na and 2.3- to 2.7-fold increase in late I Na compared with controls was evident for S287R-, T372M-, and G460S-SNTA1 and was reversed by a neuronal nitric oxide synthase inhibitor. These 3 mutations also caused a significant depolarizing shift in channel inactivation, thereby increasing the overlap of the activation and inactivation curves to increase window current. Conclusions— Abnormal biophysical phenotypes implicate mutations in SNTA1 as a novel pathogenic mechanism for the subset of channelopathic SIDS. Functional studies are essential to distinguish pathogenic perturbations in channel interacting proteins such as α1-syntrophin from similarly rare but innocuous ones.
The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis
Wertheim, Gerald , Yang, Thomas, Ramne, Anna, Liu, Zhandong , Gardner, Heather Perry, Dugan, Katherine D., Kristel, Petra, Kreike, Bas , Vijver, Marc J. van de , Cardiff, Robert D. , Reynolds, Carol, Pan, Tien-Chi , Chodosh, Lewis A.

Mayo Clinic

Proceedings of the National Academy of Sciences | August 28, 2009 | Volume: 106 | Issue: 37 | Pages: 15855-15860

10.1073/pnas.0906993106 | PMID 19717424 Get It

We previously identified a SNF1/AMPK-related protein kinase, Hunk, from a mammary tumor arising in an MMTV-neu transgenic mouse. The function of this kinase is unknown. Using targeted deletion in mice, we now demonstrate that Hunk is required for the metastasis of c-myc-induced mammary tumors, but is dispensable for normal development. Reconstitution experiments revealed that Hunk is sufficient to restore the metastatic potential of Hunk-deficient tumor cells, as well as defects in migration and invasion, and does so in a manner that requires its kinase activity. Consistent with a role for this kinase in the progression of human cancers, the human homologue of Hunk is overexpressed in aggressive subsets of carcinomas of the ovary, colon, and breast. In addition, a murine gene expression signature that distinguishes Hunk-wild type from Hunk-deficient mammary tumors predicts clinical outcome in women with breast cancer in a manner consistent with the pro-metastatic function of Hunk in mice. These findings identify a direct role for Hunk kinase activity in metastasis and establish an in vivo function for this kinase.
Analysis of the Plasma Peptidome from Pancreas Cancer Patients Connects a Peptide in Plasma to Overexpression of the Parent Protein in Tumors
Antwi, Kwasi, Demeure, Michael J. , Katchman, Benjamin A. , Decker, G. Anton , Ruiz, Yvette , Sielaff, Timothy D., Koep, Lawrence J., Lake, Douglas F. , Hostetter, Galen H.

Mayo Clinic

Journal of Proteome Research | August 22, 2009 | Volume: 8 | Issue: 10 | Pages: 4722-4731

10.1021/pr900414f | PMID 19795908 Get It

Induction of Antigen-Specific Tolerance by Oral Administration of Lactococcus lactis Delivered Immunodominant DQ8-Restricted Gliadin Peptide in Sensitized Nonobese Diabetic Ab° Dq8 Transgenic Mice
Huibregtse, Inge L., Marietta, Eric, Rashtak, Shadi , Koning, Frits , Rottiers, Pieter , David, Chella S., Deventer, Sander J. H. van, Murray, Joseph A. , Murray, J A

Mayo Clinic

The Journal of Immunology | July 28, 2009 | Volume: 183 | Issue: 4 | Pages: 2390-2396

10.4049/jimmunol.0802891 | PMID 19635921 Get It

Abstract Active delivery of recombinant autoantigens or allergens at the intestinal mucosa by genetically modified Lactococcus lactis (LL) provides a novel therapeutic approach for the induction of tolerance. Celiac disease is associated with either HLA-DQ2- or HLA-DQ8-restricted responses to specific antigenic epitopes of gliadin, and may be treated by induction of Ag-specific tolerance. We investigated whether oral administration of LL-delivered DQ8-specific gliadin epitope induces Ag-specific tolerance. LL was engineered to secrete a deamidated DQ8 gliadin epitope (LL-eDQ8d) and the induction of Ag-specific tolerance was studied in NOD AB° DQ8 transgenic mice. Tolerance was assessed by delayed-type hypersensitivity reaction, cytokine measurements, eDQ8d-specific proliferation, and regulatory T cell analysis. Oral administration of LL-eDQ8d induced suppression of local and systemic DQ8-restricted T cell responses in NOD AB° DQ8 transgenic mice. Treatment resulted in an Ag-specific decrease of the proliferative capacity of inguinal lymph node (ILN) cells and lamina propria cells. Production of IL-10 and TGF-β and a significant induction of Foxp3+ regulatory T cells were associated with the eDQ8d-specific suppression induced by LL-eDQ8d. These data provide support for the development of effective therapeutic approaches for gluten-sensitive disorders using orally administered Ag-secreting LL. Such treatments may be effective even in the setting of established hypersensitivity.
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Greenberg, Peter L. , Sun, Zhuoxin , Miller, Kenneth B., Bennett, John M. , Tallman, Martin S. , Dewald, Gordon W., Paietta, Elisabeth , Jagt, Richard van der , Houston, Jessie G., Thomas, Mary L., Cella, David , Rowe, Jacob M.

Mayo Clinic

Blood | June 29, 2009 | Volume: 114 | Issue: 12 | Pages: 2393-2400

10.1182/blood-2009-03-211797 | PMID 19564636 Get It

Abstract This phase 3 prospective randomized trial evaluated the efficacy and long-term safety of erythropoietin (EPO) with or without granulocyte colony-stimulating factor plus supportive care (SC; n = 53) versus SC alone (n = 57) for the treatment of anemic patients with lower-risk myelodysplastic syndromes. The response rates in the EPO versus SC alone arms were 36% versus 9.6%, respectively, at the initial treatment step, 47% in the EPO arm, including subsequent steps. Responding patients had significantly lower serum EPO levels (45% vs 5% responses for levels < 200 mU/mL vs ≥ 200 mU/mL) and improvement in multiple quality-of-life domains. With prolonged follow-up (median, 5.8 years), no differences were found in overall survival of patients in the EPO versus SC arms (median, 3.1 vs 2.6 years) or in the incidence of transformation to acute myeloid leukemia (7.5% and 10.5% patients, respectively). Increased survival was demonstrated for erythroid responders versus nonresponders (median, 5.5 vs 2.3 years). Flow cytometric analysis showed that the percentage of P-glycoprotein+ CD34+ marrow blasts was positively correlated with longer overall survival. In comparison with SC alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation.
O1‐03‐07: Progranulin correlates with dense‐core plaque burden in Alzheimer's disease mouse models
Pereson, Sandra, Kleinberger, Gernot , Wils, Hans , McGowan, Eileen , Jucker, Mathias , Deforce, Dieter L. D. , Broeckhoven, Christine Van , Kumar‐Singh, Samir

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2009.05.211 Get It